{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:41:54Z","timestamp":1784335314951,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clml.2021.01.022","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T21:38:08Z","timestamp":1612561088000},"page":"e559-e568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9290-4626","authenticated-orcid":false,"given":"Eshrak","family":"Al-Shaibani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunu","family":"Cyriac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Al-Shaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Gerbitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.01.022_bib1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bmt.2010.94","article-title":"How we approach patient evaluation for hematopoietic stem cell transplantation","volume":"45","author":"Hamadani","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib2","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2011.06.005","article-title":"Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission","volume":"17","author":"Farag","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib3","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2012.43.4258","article-title":"Acute myeloid leukemia in first remission: to choose transplantation or not?","volume":"31","author":"Stone","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.022_bib4","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.022_bib5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11912-013-0340-6","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how","volume":"15","author":"Magenau","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2021.01.022_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.clml.2021.01.022_bib7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/bmt.2013.71","article-title":"Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR","volume":"48","author":"Michelis","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.leukres.2011.11.021","article-title":"The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients","volume":"36","author":"Savic","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.01.022_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1179\/102453312X13221316477651","article-title":"Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia","volume":"17","author":"Djunic","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2021.01.022_bib10","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.022_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.01.022_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0609.2011.01580.x","article-title":"Modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants","volume":"86","author":"Hemmati","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.01.022_bib13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2009.011809","article-title":"A\u00a0modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia","volume":"95","author":"Terwey","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.01.022_bib14","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2014.59.1339","article-title":"Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party retrospective data mining study","volume":"33","author":"Shouval","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.022_bib15","first-page":"1","article-title":"Interpretable boosted decision trees for prediction of mortality following allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Shouval","year":"2015","journal-title":"J\u00a0Data Mining Genomics Proteomics"},{"key":"10.1016\/j.clml.2021.01.022_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.24677","article-title":"Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort","volume":"92","author":"Shouval","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.01.022_bib17","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.clml.2014.09.014","article-title":"Modified EBMT pretransplant risk score can identify favorable-risk patients undergoing allogeneic hematopoietic cell transplantation for AML, not identified by the HCT-CI score","volume":"15","author":"Michelis","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.01.022_bib18","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3109\/10428194.2015.1124990","article-title":"Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation","volume":"57","author":"Chang","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.01.022_bib19","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.bbmt.2011.06.009","article-title":"The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index","volume":"17","author":"Birninger","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/bmt.2010.227","article-title":"Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT","volume":"46","author":"Castagna","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib22","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib23","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.022_bib24","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.022_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10635150490522304","article-title":"Model selection and model averaging in phylogenetics: advantages of Akaike information criterion and Bayesian approaches over likelihood ratio tests","volume":"53","author":"Posada","year":"2004","journal-title":"Syst Biol"},{"key":"10.1016\/j.clml.2021.01.022_bib26","first-page":"117","article-title":"[A new multi-factor risk score system for predicting the outcome after allogenic hematopoietic stem cell transplantation]","volume":"22","author":"Liu","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2021.01.022_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2021.01.022_bib28","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/sim.1802","article-title":"Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation","volume":"23","author":"Pencina","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2021.01.022_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jpainsymman.2009.06.013","article-title":"Evaluating correlation and interrater reliability for four performance scales in the palliative care setting","volume":"39","author":"Myers","year":"2010","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.clml.2021.01.022_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood-2018-09-876284","article-title":"The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases","volume":"133","author":"Thakar","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.022_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbmt.2013.10.011","volume":"20","author":"Barba","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib32","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.bbmt.2014.05.005","article-title":"\u201cTo combine or not to combine:\u201d optimizing risk assessment before allogeneic hematopoietic cell transplantation","volume":"20","author":"ElSawy","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib33","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/bloodadvances.2019032268","article-title":"External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Shouval","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.01.022_bib34","article-title":"Comparison of risk scoring systems in HLA-matched related allogeneic hematopoietic stem cell transplantation: a retrospective cohort study","author":"Alada\u011f","year":"2020","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.clml.2021.01.022_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.13000","article-title":"Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia","volume":"100","author":"Khalil","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.01.022_bib36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2014.10.011","article-title":"Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?","volume":"21","author":"Hurley","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1702783","article-title":"Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction","volume":"27","author":"Fujimaki","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.022_bib38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2014.315","article-title":"Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT","volume":"50","author":"Takano","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:48Z","timestamp":1761870948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2152265021000392"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}